Reveal Genomics has announced the start of a prospective study in collaboration with the Dana-Farber Cancer Institute to evaluate the turnaround time of the HER2DX genomic test for its feasibility in clinical practice in the US. The HER2DX test results are currently generated and managed in Spain.

The HER2DX is a standardized 27-gene expression test for early-stage HER2+ breast cancer patients. It integrates clinical information with biological information tracking immune response, luminal differentiation, tumor cell proliferation, and HER2 17q12-21 chromosomal amplicon expression. 

According to the company, the test predicts the risk of relapse score, response to anti-HER2-based treatment before surgery (pCR likelihood score), and the quantitative expression of ERBB2 mRNA across HER2-negative, HER2-low, and HER2+ breast cancer (ERBB2 score).

Reveal Genomics is a biotechnology company headquartered in Spain focused on precision oncology through genomic diagnostics. It aims to improve cancer treatment by developing diagnostic tests that leverage comprehensive genomic and clinical data. Its flagship product, HER2DX, is a genomic test specifically designed for HER2-positive breast cancer, providing prognostic and predictive insights to tailor treatment strategies​.